Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent

  • Hassan Ranjbar
  • Ali Bahrami-Samani
  • Davood Beiki
  • Simindokht Shirvani-Arani
  • Mohammad Ghannadi-Maragheh
Article
First Online:
Received:

Abstract

In this work, the cocktail complex 153Sm/177Lu-EDTMP was prepared in high radiochemical purity (more than 99 %) using in house synthesized EDTMP ligand for obtaining a possible synergistic wide range palliative agent. The mixture was administered to wild-type rats and biodistribution data collected after 2 h to 7 days showed at least 70 % accumulation of the radioactivity in the bone tissues. Scintigraphic images were taken from wild-type rats injected with 153Sm/177Lu-EDTMP after 24 h and the biodistribution was shown to be consistent with post-mortem data. A comparative accumulation study was performed for vital organs up to 7 days. 153Sm/177Lu-EDTMP seemed a promising agent for bone pain palliation therapy in skeletal metastases in humans as a novel combined radiopharmaceutical.

Keywords

153Sm/177Lu-EDTMP Combined radiopharmaceutical Biodistribution Pain palliation Bone metastases 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

Authors wish to thank Tehran Research Reactor colleagues for their support and Mr. M. Mazidi for conducting animal studies.

Conflicts of interest

The authors report no conflicts of interest in this work.

References

  1. 1.
    Anderson P, Nuñez R (2007) Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 7:1517–1527CrossRefGoogle Scholar
  2. 2.
    Campa JA 3rd, Payne R (1992) The management of intractable bone pain: a clinician’s perspective. Semin Nucl Med 22(1):3–10CrossRefGoogle Scholar
  3. 3.
    Ayati N, Aryana K, Jalilian A, Hoseinnejad T, Bahrami Samani A, Ayati Z, Shariati F, Zakavi SR (2013) Treatment efficacy of 153Sm-EDTMP for painful bone metastasis. Asia Ocean J Nucl Med Biol 1:27–31Google Scholar
  4. 4.
    Beiki D, Fallahi B, Keyvan A (2013) Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases. Iran J Nucl Med 21(1):26–32Google Scholar
  5. 5.
    Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L (2014) 153Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res (in press)Google Scholar
  6. 6.
    Pacilio M, Ventroni G, Basile C, Ialongo P, Becci D, Mango L (2014) Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging 41(2):238–252CrossRefGoogle Scholar
  7. 7.
    Iakovou I, Doumas A, Badiavas K, Mpalaris V, Frangos S, Farmakis G (2014) Pain palliative therapy in women with breast cancer osseous metastatic disease and the role of specific serum cytokines as prognostic factors. Cancer Biother Radiopharm 29(3):116–123CrossRefGoogle Scholar
  8. 8.
    Rubini G, Nicoletti A, Rubini D, Asabella AN (2014) Radiometabolic treatment of bone-metastasizing cancer: from 186Rhenium to 223Radium. Cancer Biother Radiopharm 29(1):1–11CrossRefGoogle Scholar
  9. 9.
    Pirayesh E, Amoui M, Mirzaee HR, Tabei F, Rakhsha A, Kalantari BA, Shafiei B, Assadi M, Asli IN (2013) Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. J Nucl Med Technol 41(3):192–196CrossRefGoogle Scholar
  10. 10.
    Zenda S, Nakagami Y, Toshima M, Arahira S, Kawashima M, Matsumoto Y, Kinoshita H, Satake M, Akimoto T (2013) Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin OncolGoogle Scholar
  11. 11.
    Kuroda I (2014) Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med 28(1):11–16CrossRefGoogle Scholar
  12. 12.
    Baumann G, Charette M, Reid R, Sathya J (2005) Radiopharmaceuticals for the palliation of painful bone metastases: a systematic review. Radiother Oncol 75(3):258–270CrossRefGoogle Scholar
  13. 13.
    Liepe K, Runge R, Kotzerke J (2005) The benefit of bone seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131(1):60–66CrossRefGoogle Scholar
  14. 14.
    Lass P (2001) Radionuclide treatment of bone metastases—current concepts and trends. Nucl Med Rev Cent East Eur 4(1):1–3Google Scholar
  15. 15.
    Hosain F, Spencer RP (1992) Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin Nucl Med 22:11–16CrossRefGoogle Scholar
  16. 16.
    Volkert WA, Hoffman TJ (1999) Therapeutic radiopharmaceuticals. Chem Rev 99:2269–2292CrossRefGoogle Scholar
  17. 17.
    Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, Polyák A, Máthé D, Venkatesh M, Janoki G (2008) 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm 23:202–213CrossRefGoogle Scholar
  18. 18.
    Ando A, Ando I, Tonami N, Kinuya S, Kajuma K, Kataiwa A, Nakagawa M, Fujita N (1998) 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun 19:587–591CrossRefGoogle Scholar
  19. 19.
    Laznicek M, Lazincova A, Budsky F, Prokop J, Kopika K (1994) Comparison of biological characteristics of EDTMP complexes with 99mTc, 111In and 153Sm in rats. Appl Radiat Isot 45:949–953CrossRefGoogle Scholar
  20. 20.
    Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45(8):1358–1365Google Scholar
  21. 21.
    Shinto AS, Shibu D, Kamaleshwaran KK, Das T, Chakraborty S, Banerjee S, Thirumalaisamy P, Das P, Veersekar G (2014) 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Tech 42:55–61CrossRefGoogle Scholar
  22. 22.
    Alavi MS (2010) Clinical trial project: Lu-177-EDTMP for Bone pain palliation of bone metastasis in breast cancer [Project]. Shiraz University of Medical Sciences, Nuclear Medicine CenterGoogle Scholar
  23. 23.
    Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N (2003) Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 59:109–117CrossRefGoogle Scholar
  24. 24.
    Sola GAR, Arguelles MG, Bottazzini DL, Furnari JC, Parada IG, Rojo A, Ruiz HV (2000) Lutetium-177–EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim Acta 88:157–161Google Scholar
  25. 25.
    International Atomic Energy Agency (IAEA), VIENNA, Manual for reactor produced radioisotopes. IAEA-TECDOC-1340, ISBN 92-0-101103-2, ISSN 1011–4289, Austria, January 2003Google Scholar
  26. 26.
    Goeckeler WF, Troutner DE, Volkert WA, Edwards B, Simon J, Wilson D (1986) 153Sm radiotherapeutic bone agents. Int J Rad Appl Instrum B 13(4):479–482CrossRefGoogle Scholar
  27. 27.
    EANM Radiopharmacy Committee (2007) Guidelines on current good radiopharmacy, practice (cGRPP) in the preparation of radiopharmaceuticals. Version 2. Comm Bruss 2:112–115Google Scholar
  28. 28.
    Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G (2013) Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. J Nucl Med 54(9):1535–1542CrossRefGoogle Scholar
  29. 29.
    Sohaib M, Ahmad M, Jehangir M, Perveen A (2011) Ethylene diamine tetramethylene phosphonic acid labeled with various β–emitting radiometals: labeling optimization and animal biodistribution. Cancer Biother Radiopharm 26(2):159–164CrossRefGoogle Scholar
  30. 30.
    Bahrami-Samani A, Ghannadi-Maragheh M, Jalilian AR, Meftahi M, Shirvani-Arani S, Moradkhani S (2009) Production, quality control and biological evaluation of 153Sm-EDTMP in wild-type rodents. Iran J Nucl Med 17:12–19Google Scholar
  31. 31.
    Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, Zaknun JJ, Pillai MR, Jánoki GA (2010) Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP. A potential bone pain palliation agent. Nucl Med Biol 37:215–226CrossRefGoogle Scholar
  32. 32.
    Bahrami-Samani A, Anvari A, Jalilian AR, Shirvani-Arani S, Yousefnia H, Aghamiri MR, Ghannadi-Maragheh M (2012) Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res 11(1):137–144Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2014

Authors and Affiliations

  • Hassan Ranjbar
    • 1
  • Ali Bahrami-Samani
    • 1
  • Davood Beiki
    • 2
  • Simindokht Shirvani-Arani
    • 1
  • Mohammad Ghannadi-Maragheh
    • 1
  1. 1.Radiopharmaceutical Research and Development Lab (RRDL)Nuclear Science and Technology Research Institute (NSTRI)TehranIran
  2. 2.Research Center for Nuclear MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations